Skip to main content Accessibility help
×
Home

Cardiac Electrophysiology Laboratories: A Potential Target for Antimicrobial Stewardship and Quality Improvement?

  • Westyn Branch-Elliman (a1) (a2) (a3), Maggie Stanislawski (a3), Judith Strymish (a4) (a5), Anna E. Barón (a2) (a3) (a6), Kalpana Gupta (a4) (a7), Paul D. Varosy (a1) (a2) (a3), Howard S. Gold (a5) (a8) and P. Michael Ho (a1) (a2) (a3)...

Abstract

BACKGROUND

Infections following cardiovascular implantable electronic device (CIED) procedures, including pacemaker and implantable cardioverter–defibrillators, are devastating and costly. Preimplantation prophylactic antimicrobials are effective for reducing postprocedural infections. However, routine postprocedural antimicrobials are not associated with improved outcomes, and they may be harmful. Thus, we sought to characterize antimicrobial use patterns following CIED procedures.

DESIGN

All patients who underwent CIED procedures from October 1, 2007 to September 30, 2013 and had procedural information entered into the VA Clinical Assessment Reporting and Tracking (CART) software program were included in this study. All antibiotic prescriptions lasting more than 24 hours following device implantation or revision were identified using pharmacy databases, and postprocedural antibiotic use lasting more than 24 hours was characterized.

RESULTS

In total, 3,712 CIED procedures were performed at 34 VA facilities on 3,570 patients with a mean age of 71.7 years (standard deviation [SD], 11.1 years), 98.4% of whom were male. Postprocedural antibiotics >24 hours were prescribed following 1,579 of 3,712 CIED procedures (42.5%). The median duration of therapy was 5 days (interquartile range [IQR], 3–7 days). The most commonly prescribed antibiotic was cephalexin (1,152 of 1,579; 72.9%), followed by doxycycline (118 of 1,579; 7.47%) and ciprofloxacin (93 of 1,579; 5.9%). Vancomycin was used in 73 of 1,579 prescriptions (4.62%). Among the highest quartile of procedural volume, prescribing practices varied considerably, ranging from 3.2% to 77.6%.

CONCLUSIONS

Nearly 1 in 2 patients received prolonged postprocedural antimicrobial therapy following CIED procedures, and the rate of postprocedural antimicrobial therapy use varied considerably by facility. Given the lack of demonstrated benefit of routine prolonged antimicrobial therapy following CIED procedures, antimicrobial use following cardiac device interventions may be a potential target for quality improvement programs and antimicrobial stewardship.

Infect Control Hosp Epidemiol 2016;37:1005–1011

Copyright

Corresponding author

Address correspondence to Westyn Branch-Elliman, MD, MMSc, Boston VA Healthcare System, 1400 VFW Parkway, West Roxbury, MA (Westyn.Branch-Elliman@VA.gov).

References

Hide All
1. Zhan, C, Baine, WB, Sedrakyan, A, Steiner, C. Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. J Gen Internal Med 2008;23:S13S19.
2. Bradshaw, PJ, Stobie, P, Knuiman, MW, Briffa, TG, Hobbs, MS. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart 2014;1:e000177.
3. Epstein, AE, DiMarco, JP, Ellenbogen, KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1e62.
4. Tracy, CM, Epstein, AE, Darbar, D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:12971313.
5. Voigt, A, Shalaby, A, Saba, S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol 2006;48:590591.
6. Greenspon, AJ, Patel, JD, Lau, E, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011;58:10011006.
7. Voigt, A, Shalaby, A, Saba, S. Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. PACE 2010;33:414419.
8. Sohail, MR, Henrikson, CA, Braid-Forbes, MJ, Forbes, KF, Lerner, DJ. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Internal Med 2011;171:18211828.
9. Margey, R, McCann, H, Blake, G, et al. Contemporary management of and outcomes from cardiac device related infections. Europace 2010;12:6470.
10. Sandoe, JA, Barlow, G, Chambers, JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint working party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother 2015;70:325359.
11. Bratzler, DW, Dellinger, EP, Olsen, KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. AJHP 2013;70:195283.
12. Tsai, TT, Box, TL, Gethoffer, H, et al. Feasibility of proactive medical device surveillance: the VA Clinical Assessment Reporting and Tracking (CART) program. Med Care 2013;51:S57S61.
13. Maddox, TM, Plomondon, ME, Petrich, M, et al. A national clinical quality program for Veterans Affairs catheterization laboratories (from the Veterans Affairs clinical assessment, reporting, and tracking program). Am J Cardiol 2014;114:17501757.
14. Darouiche, R, Mosier, M, Voigt, J. Antibiotics and antiseptics to prevent infection in cardiac rhythm management device implantation surgery. PACE 2012;35:13481360.
15. de Oliveira, JC, Martinelli, M, Nishioka, SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circulation Arrhyth Electrophys 2009;2:2934.
16. Carignan, A, Allard, C, Pepin, J, Cossette, B, Nault, V, Valiquette, L. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 2008;46:18381843.
17. Harbarth, S, Samore, MH, Lichtenberg, D, Carmeli, Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:29162921.
18. McDonald, M, Grabsch, E, Marshall, C, Forbes, A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Austr NZ J Surg 1998;68:388396.
19. Remmelts, HH, Meine, M, Loh, P, et al. Infection after ICD implantation: operating room versus cardiac catheterisation laboratory. Netherl Heart J 2009;17:95100.
20. The Joint Commission. Surgical Care Improvement Project. 2006. http://www.jointcommission.org/surgical_care_improvement_project/. Accessed October 15, 2015.
21. Drekonja, D, Filice, G, Greer, N, et al. Antimicrobial Stewardship Programs in Outpatient Settings: A Systematic Review. Washington, DC: Department of Veteran Affairs, 2014.
22. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012;33:322–327.
23. Darda, S, Khouri, Y, Gorges, R, et al. Feasibility and safety of same-day discharge after implantable cardioverter defibrillator placement for primary prevention. PACE 2013;36:885891.
24. Baddour, LM, Epstein, AE, Erickson, CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458477.
25. Cengiz, M, Okutucu, S, Ascioglu, S, et al. Permanent pacemaker and implantable cardioverter defibrillator infections: seven years of diagnostic and therapeutic experience of a single center. Clin Cardiol 2010;33:406411.
26. Lin, YS, Hung, SP, Chen, PR, et al. Risk factors influencing complications of cardiac implantable electronic device implantation: infection, pneumothorax and heart perforation: a nationwide population-based cohort study. Medicine 2014;93:e213.
27. Nery, PB, Fernandes, R, Nair, GM, et al. Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. J Cardiovasc Electrophysiol 2010;21:786790.
28. Sohail, MR, Uslan, DZ, Khan, AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007;45:166173.
29. Lewis, AB, Hayes, DL, Holmes, DR Jr., Vlietstra, RE, Pluth, JR, Osborn, MJ. Update on infections involving permanent pacemakers. Characterization and management. J Thorac Cardiovasc Surg 1985;89:758763.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed